+1-786-628-7980
Sign Up/Sign In 
In response to the swift progress in nucleic acid therapeutics, pharmaceutical companies have partnered with contract development and manufacturing organizations (CDMOs). This outsourcing trend, coupled with the rising pharmaceutical demand, has led to the global expansion of the nucleic acid therapeutics CDMO market.
The Asia-Pacific (APAC) region is witnessing the most rapid growth as a market for nucleic acid therapeutics. Governments in the Asia-Pacific are also providing significant support to facilitate the advancement and production of nucleic acid therapeutics.
The APAC nucleic acid therapeutics CDMO market is expected to reach $4.04 billion by 2033 from $0.97 billion in 2022, at a CAGR of 13.92% during the forecast period 2023-2033.
The APAC nucleic acid therapeutics CDMO market is influenced by two significant trends. Firstly, there is a notable surge in investment aimed at expanding CDMO manufacturing units to meet the increasing demand. This includes the acquisition of new facilities, the upgradation of existing ones, and the adoption of advanced technologies to enhance efficiency.
CDMOs are strategically shifting from traditional manufacturing roles to more innovative and diversified services. They are investing in new facilities to support emerging therapeutic modalities and adjusting their operations to accommodate smaller, varied projects. This transformation is propelled by partnerships and acquisitions, empowering CDMOs to play a more significant role in the evolution of the pharmaceutical industry, especially in areas such as vaccine production.
BIS Research, a leading market research firm, has released a report titled, Asia-Pacific nucleic acid therapeutics CDMO market, which discusses the challenges, growth factors, and future opportunities driving the remarkable growth of the Asia-Pacific nucleic acid therapeutics CDMO market.
Some major companies operating in the APAC nucleic acid therapeutics CDMO market are:
The BIS Research report on the APAC nucleic acid therapeutics CDMO market is segmented by chemical synthesis methods and regions. The solid-phase oligonucleotide synthesis (SPOS) category dominated the market based on chemical synthesis methods in 2022, and this dominance is expected to continue from 2023 to 2033. Furthermore, substantial growth is anticipated in the liquid-phase oligonucleotide synthesis (LPOS) segment, with a projected CAGR of 18.43% throughout the forecast period 2023-2033.
China secured the largest market share in the region in 2022, and this trend is anticipated to persist during the forecast period from 2023-2033.
The significant presence of established pharmaceutical players in APAC emerges as a crucial driver, promising considerable short-term and moderate long-term impacts on the APAC nucleic acid therapeutics CDMO market. Continued government funding and support are also vital in fostering research and development of nucleic acid therapeutics. Additionally, APAC’s relatively low manufacturing costs are poised to attract pharmaceutical companies, acting as a driving force for the market.
Opportunities arise from the global market expansion as outsourcing gains traction, leading to increased partnerships and collaborations. The diverse services offered by APAC CDMOs provide pharmaceutical companies with a spectrum of expertise.
Nevertheless, the high cost of synthesized oligonucleotides and a shortage of skilled professionals are anticipated to pose challenges and restrain the growth of the APAC nucleic acid therapeutics CDMO market.
The APAC nucleic acid therapeutics CDMO market report provides a credible global and regional market analysis. The report profiles existing and upcoming products, types, applications, end users, and key players in the market.
BIS Research follows an effective market intelligence methodology comprising a crucial 15-step process. Data is captured from reliable, intelligent sources such as expert interviews, patents, web analytics, scholarly articles, scientific publications, and research and development literature.
BIS follows the Deep Tech M-A-P™ approach, which includes market, application, and product within the syndicate and custom research projects.
M– The Market section covers industry overview, business dynamics, competitive benchmarks, and company profiles. It provides insights to enter, expand, or exit markets globally, regionally, or locally.
A– The Application section delves into product analyses, technology insights, use cases, and user types. This data is backed by precise market estimates and forecasts.
P– The Product section covers products, parts, technologies, and materials. Companies looking to drive an innovative agenda need information about product definitions, demand analysis, technology benchmarking and roadmaps, patents, and pricing analysis.
BIS Research healthcare analyst suggests, “In addition to traditional business models, CDMOs are now exploring fresh and inventive approaches. They are transitioning toward a comprehensive “one-stop-shop” service model within the CDMO value chain. These novel models emphasize addressing CDMOs’ manufacturing deficiencies and are particularly dedicated to developing their drug portfolios.”
BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.
Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.
Head of Marketing
Email: media@bisresearch.com
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT, CA 94538-1686
Visit our Blog @https://bisresearch.com/insights
Get Expert Insights @https://community.insightmonk.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch
